Altered expression of p53 and MDM2 proteins in hematological malignancies

Neoplasma

Volumn 50, Issue 1, 2003, Pages 31-40

  Konikova E ^a   Kusenda, J ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Flow cytometry; Leukemia cells; MDM2; p53

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; B CELL LEUKEMIA; B LYMPHOBLAST; B LYMPHOCYTE; BONE MARROW CELL; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CELL POPULATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMOGENESIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOBLAST;

EID: 0037263346     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. ALARCON-VARGAS D, RONAI Z. p53-MDM2-the affair that never ends. Carcinogenesis 2002; 23: 541-547.
2. BABUŠÍKOVA O, GLASOVÁ M, KONÍKOVÁ E, KUSENDA J, ČÁP J, GYARFÁŠ J, KOUBEK K. Phenotypic heterogeneity and aberrant markers expression in T-cell leukemia. Neoplasma 1998;45:128-133.
3. BUESO-RAMOS C, MANSHOURI T, HAIDAR MA, HUH YO, KEATING MI, ALBITAR M. Multiple patterns of MDM-2 deregulation in human leukemias: Implications in leukemogenesis and prognosis. Leuk Lymphoma 1995; 17: 13-18.
4. CAPOULADE C, MIR LM, CARLIER K, LÉCLUSE Y, TÉTAUD C, MISHAL Z, WIELS J. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood 2001; 97: 1043-1049.
5. CORDONE I, MASI S, MAURO FR., SODDU S, MORSILLI O, VALENTINI T, VEGNA ML, GUGLIELMI C, MANCINI F, GIULIACCI S, SACCHI A, MANDELI F, FOA R. p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 1998; 91: 4342-4349.
6. DONEHOWER LA, BRADLEY A. The tumor suppressor p53. Biochim Biophys Acta 1993; 1155: 181-205.
7. DRACH D, DRACH J, GLASSI H, GATTRINGER C, HUBER H. Flow cytometric detection of cytoplasmic antigens in acute leukemias: Implications for lineage assignment. Leukemia Res 1993; 17: 455-461.
8. FREEDMAN DA, LEVINE AJ. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eight G.H.A. Clowes memorial award lecture. Cancer Res 1999; 59: 1-7.
9. GUSTAFSSON B, CHRISTENSON B, GUSTAFSSON Be, HJALMAR V, WINIARSKI J. Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Ped Oncology 2000; 34: 117-124.
10. HAIDAR MA, EL-HAJJ H, BUESO-RAMOS CE, MANSHOURI T, GLASSMAN A, KEATING MJ, MAHER A. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am J Hematol 1997; 54: 189-195.
11. KASTAN MB, RADIN AI, KUERBITZ SJ, ONYEKWERE O, WOLKOW CA, CIVIN CI, STONE KD, WOO T, RAVINDRANATH Y, CRAIG WR. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 1991; 51: 4279-4286.
12. KONÍKOVÁ E, BABUŠÍKOVÁ O, KUSENDA J. Flow cytometry of p53 protein expression in some hematological malignancies. Neoplasma 1999; 46: 368-376.
13. KONÍKOVÁ E, KUSENDA J. p53 protein expression in human leukemia and lymphoma cells. Neoplasma 2001; 48: 290-298.
14. waf1/CIP1 expression in SCID mice Epstein Barr Virus induced lymphoproliferation. J Histochem Cytochem 1999; 47: 1315-1321.
15. MOSNER J, DEPPERT W. p53 and MDM2 are expressed independently during cellular proliferation. Oncogene 1994; 9: 3321-3328.
16. PAN Y, HAINES DS. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells. Cancer Res 1999; 59: 2064-2067.
17. PRIVES C. Signaling to p53: Breaking the MDM2-p53 circuit. Cell 1998; 95: 5-8.
18. RIVAS CI, WISNIEWSKI D, STRIFE A, PEREZ A, LAMBEK C, BRUNO S, DARZYNKIEWICZ ZC. Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood 1992; 79: 1982-1986.
19. SCHOTTELIUS A, BRENNSCHEIDT U, LUDWIG WD, MERTELSMANN RR, HERRMAN F, LUBBERT M. Mechanism of p53 alteration in acute leukemias. Leukemia 1994; 8: 1673-1681.
20. STEFANAKI K, TZARDI M, KOUVIDOU CH, CHANIOTIS V, BOLIOTI M, VLYCHOU M, ZOIS M, KAKOLYRIS S, DELIDES G, RONTOGIANNI D, GEORGOULIAS V, KANAVAROS P. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res 1998; 18: 2403-2408.
21. ARF-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood 2000; 12: 3939-3944.
22. TEOH G, URASHIMA M, OGATA A, CHAUHAN D, DECAPRIO JA, TREON SP, SCHLOSSMAN RL, ANDERSON KC. MDM2 protein overexpression promotes proliferation and survival of multiple melanoma cells. Blood 1997; 90: 1982-1992.
23. UNGAR S, VAN DE MAEREN A, TAMILEHTO L, LINNAINMAA K, MATTSON K, GERWIN BI. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer 1996; 74: 1534-1540.
24. URASHIMA M, TEOH G, CHAUHAN D, OGATA A, SHIRAHAMA S, KAIHARA C, MATSUZAKI M, MATSUSHIMA H, AKIYAMA M, YUZA Y, MAEKAWA K, ANDERSON KC. MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells. Blood 1998; 92: 959-967.
25. VOJTESEK B, DOLEZALOVA H, LAUEROVA L, SVITAKOVA M, HAVLIS P, KOVARIK J, MIDGLEY CA, LANE DP. Conformational changes in p53 analyzed using new antibodies to the core DNA binding domain of the protein. Oncogene 1995; 10: 389-393.
26. WATANABE T, ICHIKAWA A, SAITO H, HOTTA T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 1996; 21: 391-397.
27. ZHENG A, CASTREN K, SÄILLY M, SAVOLAINEN ER, KOISTINEN P, VÄHÄKANGAS K. p53 status of newly established acute myeloid leukemia cell lines. Brit J Cancer 1999; 79: 407-415.
28. ZHOU M, HEAGER AM, SMITH SD, FINDLEY HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995; 85: 1608-1614.
29. ZHOU M, GU L, ABSHIRE TC, HOMANS A, BILLETT AL, YEAGER AM, FINDLEY HW. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 61-67.